Dry Days: State Weighs Fireworks Ban As Some Communities Prohibit Them - DETAILS HERE
Esperion Therapeutics Presents Promising Test Results On Cholesterol DrugThe pharma startup Esperion Therapeutics Inc. Monday announced full results of a Phase 2 clincal study of its lead drug candidate, called ETC-1002. The drug is intended to reduce high cholesterol levels in patients with a history of intolerance to today's cholesterol-lowering statin drugs.
More Positive Test Results For Plymouth Firm's Cholesterol DrugEsperion Therapeutics Inc. Tuesday announced positive results from a Phase 2a study of its drug candidate ETC-1002 when added to statin therapy in patients with high levels of low density lipoprotein cholesterol, the so-called bad cholesterol, in their blood.

More From CBS Detroit

Hump Day Drinks: 8 Cheery Cocktail RecipesNow that you've made it through half the work week, it's time to celebrate!
Daily J

Watch & Listen